How Independent and Grocery-Chain Pharmacies Are Competing on Cash Price

Two contradictory trends are true of American pharmacy at the same time in 2026: the market for filling prescriptions has never been more consolidated, and cash-price prescribing has never had more legitimate competition driving it down. For prescribers deciding where to route a script — particularly for cash-pay or high-deductible patients — understanding both trends at once is more useful than treating either one in isolation.

The Consolidation Side of the Story

Prescription dispensing revenue in the U.S. is heavily concentrated. The top 15 pharmacy companies accounted for nearly three-quarters of total U.S. dispensing revenue in 2025, and the four largest — CVS Health, Walgreens, Cigna, and UnitedHealth Group — together accounted for more than half of it on their own [1]. That concentration has been building for over a decade: from 2010 to 2025, CVS Pharmacy and Walgreens alone announced the acquisition of more than 6,000 locations from smaller competitors [1].

Pharmacy benefit managers (PBMs) sit at the center of that concentration. The three largest PBMs — CVS Caremark, Express Scripts, and OptumRx — administer pharmacy networks that individually span tens of thousands of locations, and plan sponsors routinely shift entire member populations between them; CalPERS, for example, moved certain Medicare HMO and PPO plans from OptumRx to CVS Caremark effective January 1, 2026 under a new multi-year contract [2]. Each such transition resets which pharmacies sit inside a given patient's preferred network, independent of anything the prescriber or patient did — a structural volatility that independent pharmacies have less scale to absorb than national chains with contracts across every major PBM.

The Countertrend: Independent Pharmacies Are Still Growing

Despite that pressure, independent pharmacy counts have not collapsed — they've grown. Between 2015 and 2025, the number of independent retail pharmacies in the U.S. increased by 321 stores, a 1.4% gain, while retail chain pharmacy counts fell by 5,742 stores, a 14.1% decline over the same period [3]. That trend continued into 2026, with 67 more independent pharmacies operating nationally compared with the year before [3]. The trade association representing PBMs points to this data as evidence that reimbursement rates for independents have held up [3] — a claim worth taking with the appropriate grain of salt given the source, but the underlying store-count data is independently verifiable and tells a real story: independents are not simply being priced out of existence, even as their share of PBM-driven volume shrinks.

The mechanism behind that survival, for many independents, has shifted from insurance-network participation toward cash-price competitiveness — discount programs, direct partnerships with cash-pay platforms, and membership or subscription pricing that doesn't depend on being in a PBM's preferred network at all.

GLP-1 Pricing as the Clearest Case Study

Nowhere is the cash-price competition more visible right now than in GLP-1 weight-management drugs. In 2026, Novo Nordisk cut the cash price of Wegovy and Ozempic by 30%, from $499 to $349 per month for patients paying without insurance, extending that pricing to roughly 70,000 retail pharmacies nationwide, including Walmart and Costco [4]. Eli Lilly has taken a parallel approach with Zepbound, offering vials priced between $349 and $499 per month depending on dose through its LillyDirect program, with retail pickup available at Walmart [4].

The pattern is consistent across both manufacturers: direct-to-consumer and cash-pay pricing programs are now routinely undercutting standard insured copays for patients on high-deductible plans or without GLP-1 coverage at all, and that pricing is increasingly available through ordinary retail pharmacy pickup rather than mail-order-only programs. For prescribers, this means the "what does this actually cost without insurance" conversation has a materially different answer in 2026 than it did even a year or two earlier, and it's worth checking current cash pricing rather than relying on a remembered figure.

It's also worth noting the gap between manufacturer direct-to-consumer pricing and standard retail cash pricing at the same pharmacy chain can be substantial — as of mid-2026, a standard cash-pay box of Wegovy at a typical retail pharmacy still runs well above $1,300, compared with the $349 manufacturer-direct price for the same drug through NovoCare Pharmacy [4]. That gap means the specific channel a patient uses, not just the pharmacy chain, determines what they actually pay — a distinction worth confirming rather than assuming based on the pharmacy's name alone.

Why Independents Often Punch Above Their Weight on Service

Price is only part of what keeps independent pharmacies competitive. Independents are disproportionately more likely to offer same-day compounding, direct pharmacist consultation without an appointment, and flexibility on delivery or curbside pickup that larger chains standardize less consistently across locations. For patients on complex regimens — polypharmacy in older adults, pediatric dosing that requires compounding, or specialty conditions where a pharmacist relationship matters for adherence — those service differences can matter as much as a few dollars of price difference. None of that shows up in a PBM network directory, which is part of why prescribers who default to "in-network" as the only routing criterion may be missing options that serve a given patient better on both price and service.

What Grocery-Chain Pharmacies Bring to the Table

Grocery-chain pharmacies (Kroger, Safeway, Vons, and similar regional chains) occupy a middle position between large national chains and independents: broad geographic reach similar to a national chain, but often more willing to participate in cash-pay partnership programs the way independents do, since pharmacy is typically a traffic-driver for the grocery business rather than the sole profit center. That combination — retail-chain reach with independent-style cash-pay flexibility — is part of why cash-price partnership networks increasingly include grocery pharmacies alongside independents rather than treating them as a separate category.

What This Means for Where You Route a Script

• For cash-pay or high-deductible patients, the lowest-cost pharmacy is no longer reliably the same one it was even a year ago. Manufacturer cash-price programs and pharmacy-specific discount partnerships change faster than most prescribers can track manually.
• Independent and grocery-chain pharmacies are a legitimate cash-price option, not a fallback. The data on independent pharmacy growth suggests these locations are competing successfully on price and service, not simply surviving on inertia.
• A platform that shows real-time cash pricing across multiple pharmacy types — independent, grocery-chain, and national retail — gives a more complete picture than checking one chain's app or assuming a single "usual" pharmacy is still the cheapest option for a given patient.
• When a PBM contract transition happens (as with the CalPERS example above), a patient's previously preferred pharmacy can change without either the prescriber or patient initiating anything — worth a quick verification at the next visit for patients on maintenance medications, rather than assuming last year's pharmacy routing still applies.

Where eNavvi Fits

eNavvi's pharmacy network spans independent and grocery-chain pharmacies alongside cash-pay partners including Mark Cuban Cost Plus Drug Company and Amazon Pharmacy, letting clinicians compare real-time cash pricing across pharmacy types at the point of prescribing rather than defaulting to whichever pharmacy a patient has used before. See real-time cash pricing across pharmacy types on eNavvi.